Expressive

rs11726937 - PRDM5

Magnitude 2.2 · 1 study on file

Reported associations

  • Translational genomics of osteoarthritis in 1,962,069 individuals - Unknown journal (n.d.) · Unknown authors · PubMed 40205036

    ABSTRACT: Osteoarthritis is the third most rapidly growing health condition associated with disability, after dementia and diabetes. By 2050, the total number of patients with osteoarthritis is estimated to reach 1 billion worldwide. As no disease-modifying treatments exist for osteoarthritis, a better understanding of disease aetiopathology is urgently needed. Here we perform a genome-wide association study meta-analyses across up to 489,975 cases and 1,472,094 controls, establishing 962 independent associations, 513 of which have not been previously reported. Using single-cell multiomics data, we identify signal enrichment in embryonic skeletal development pathways. We integrate orthogonal lines of evidence, including transcriptome, proteome and epigenome profiles of primary joint tiss

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • PRDM5 osteoarthritis risk and prevention strategies Moderate

    Elevated genetic osteoarthritis risk warrants proactive clinical discussion for personalized prevention and monitoring.

Exercise

  • low-impact weight-bearing exercise Moderate

    Joint-protective exercise delays osteoarthritis progression and is particularly beneficial for carriers of OA risk alleles.

    150 min per week of moderate-intensity activity: swimming, cycling, brisk walking, or elliptical training

Lifestyle

  • weight management Moderate

    Excess body weight accelerates osteoarthritis progression; weight control is modifiable and important for risk carriers.

Screening

  • osteoarthritis screening Moderate

    PRDM5 rs11726937 A allele associates strongly with osteoarthritis risk; carriers warrant heightened surveillance beginning earlier in life.

    Clinical or radiographic assessment at age 40-45, repeat every 2-3 years